Drugs / JE-CV
last change Jul 2012 re-read 2 minutes ago

JE-CV

Vaccine

Developed for
Japanese encephalitis
Investigated by
Sanofi Pasteur, a Sanofi Company

Trials 1 · a red edge is where a trial was stopped

2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00735644 Aug 2008 → May 2009 Japanese encephalitis, hepatitis A virus infection Sanofi Pasteur, a Sanofi Company Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as JE-CV “This trial in 1200 JE-vaccination naïve children (age 12-18 mo) in Thailand and the Philippines aimed to demonstrate consistency of three successive industrial scale...” PMID 22777096 Jul 2012
Modality Vaccine “live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV)” PMID 22777096 Jul 2012
Route Subcutaneous “0.5 mL, SubcutaneousNCT00735644